Cargando…

Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies

In this retrospective study, we investigated adverse events and outcomes in patients treated with bevacizumab for ovarian, fallopian tube, or primary peritoneal cancers at a single hospital. We determined the cumulative incidences of various bevacizumab-related adverse events and the correlation bet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Shu-Ping, Hsu, Heng-Cheng, Tai, Yi-Jou, Chen, Yu-Li, Chiang, Ying-Cheng, Chen, Chi-An, Cheng, Wen-Fang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498445/ https://www.ncbi.nlm.nih.gov/pubmed/31105567 http://dx.doi.org/10.3389/fphar.2019.00426

Ejemplares similares

Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies
por: Tai, Yu-Hsiao, et al.
Publicado: (2017)

The Role of Eicosanoids in Gynecological Malignancies
por: Smith, Paige G., et al.
Publicado: (2020)

Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
por: Xun, Xueqiong, et al.
Publicado: (2023)

Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review
por: Gao, Ling, et al.
Publicado: (2019)

Increased risk of second primary malignancies among endometrial cancer survivors receiving surgery alone: A population‐based analysis
por: Lai, Yen‐Ling, et al.
Publicado: (2021)

Anticancer Effect of Tanshinones on Female Breast Cancer and Gynecological Cancer
por: Jin, Zhou, et al.
Publicado: (2022)

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
por: Wang, Peng-Fei, et al.
Publicado: (2017)

Impact of Adjuvant Modalities on Survival in Patients with Advanced Stage Endometrial Carcinoma: A Retrospective Analysis from a Tertiary Medical Center
por: Tai, Yi-Jou, et al.
Publicado: (2019)

Factors predicting parametrial invasion in patients with early-stage cervical carcinomas
por: Hsu, Heng-Cheng, et al.
Publicado: (2018)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers
por: Wang, Jin, et al.
Publicado: (2019)

Digoxin and Amiodarone on the Risk of Ischemic Stroke in Atrial Fibrillation: An Observational Study
por: Lai, Kuan-Cheng, et al.
Publicado: (2018)

Bevacizumab increases late toxicity in re-irradiation with image-guided high-dose-rate brachytherapy for gynecologic malignancies
por: Murakami, Naoya, et al.
Publicado: (2022)

Natural phytochemicals that affect autophagy in the treatment of oral diseases and infections: A review
por: Cheng, Xi, et al.
Publicado: (2022)

Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
por: Su, Si, et al.
Publicado: (2023)

Generalizability of machine learning methods in detecting adverse drug events from clinical narratives in electronic medical records
por: Zitu, Md Muntasir, et al.
Publicado: (2023)

Case report: A relatively rare adverse event caused by carbetocin— placenta interception
por: Li, Jun-Qiang, et al.
Publicado: (2023)

Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer–the Experience of a Tertiary Cancer Center
por: Căinap, Călin, et al.
Publicado: (2021)

Evaluation of the Direct Costs of Managing Adverse Drug Events in all Ages and of Avoidable Adverse Drug Events in Older Adults in Japan
por: Katsuno, Hayato, et al.
Publicado: (2021)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
por: Guo, Haoning, et al.
Publicado: (2022)

Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system
por: Guo, Qiang, et al.
Publicado: (2022)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
por: Guo, Haoning, et al.
Publicado: (2022)

Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS
por: Tian, Xiaojiang, et al.
Publicado: (2022)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
por: Cui, Zhiwei, et al.
Publicado: (2023)

Variation in adverse drug events of opioids in the United States
por: Liu, Edward Y., et al.
Publicado: (2023)

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
por: Jiao, Xue-Feng, et al.
Publicado: (2023)

A Randomized, Double-Blind, Single-Dose Study Comparing the Biosimilarity of HOT-1010 With Bevacizumab (Avastin®) in Chinese Healthy Male Subjects
por: Huang, Kai, et al.
Publicado: (2021)

Weichang’an Formula Inhibits Tumor Growth in Combination with Bevacizumab in a Murine Model of Colon Cancer—Making up for the Deficiency of Bevacizumab by inhibiting VEGFR-1
por: Pan, Chuan-Fang, et al.
Publicado: (2020)

Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity
por: Laskey, Robin A, et al.
Publicado: (2014)

Did the New Italian Law on Mandatory Vaccines Affect Adverse Event Following Immunization’s Reporting? A Pharmacovigilance Study in Southern Italy
por: Scavone, Cristina, et al.
Publicado: (2018)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Individualized approach to elexacaftor/tezacaftor/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: A case series
por: Ibrahim, Hisham, et al.
Publicado: (2023)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Shu, Yamin, et al.
Publicado: (2022)

Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting
por: Lee, Yueh-Ting, et al.
Publicado: (2021)

Current landscape and tailored management of immune-related adverse events
por: Liu, Wenhui, et al.
Publicado: (2023)

Outcome and prognostic factors of unexpected ovarian carcinomas
por: Cheng, Ching‐Yu, et al.
Publicado: (2022)

Profiling COVID-19 Vaccine Adverse Events by Statistical and Ontological Analysis of VAERS Case Reports
por: Guo, Wenxin, et al.
Publicado: (2022)

Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis
por: Li, Ju, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2ccfqm7u1r1prei0qjvr5697rd